Tuesday 12 May 2026
09:30-10:45 Meet-the-expert sessions – parallel sessions
· EUCAST and NordicAST methodology – where to look when questions arise
(Kaisu Rantakokko-Jalava, Anna Hill, Ingvild Haugan)
· Reading of disk diffusion inhibition zones – from the basic to challenging cases
(Jenny Åhman, Karianne Gammelsrud; Nathalie Friberg)
10:45-11:15 Coffee
11:15-11.30 Welcome (Barbara Holzknecht)
11:30-12:30 Session 1 - News from EUCAST and EDL (chair: Barbara Holzknecht)
· News from EUCAST and EDL (Erika Matuschek, Jenny Åhman, Barbara Holzknecht)
12:30-13:30 Lunch
13:30-14:15 Session 2 – Keynote lecture (chair Anna-Karin Smekal)
· Scientific support for rapid diagnostics with focus on rapid AST (Oskar Ekelund)
14:15-14:20 Stretch break
14:20-15:00 Session 3 – Update on AST and treatment of Gram positive infections
(chair Ingvild Haugan)
· Penicillin resistant S. dysgalactiae is it possible? (Nathalie Friberg)
· Dalbavancin for difficult to treat gram positive infections (Barbara Holzknecht)
15:00-15:30 Coffee
15:30-16:10 Session 4 – Keynote lecture (chair Arnfinn Sundsfjord)
· Does genotype overrule phenotype? (Kristin Hegstad)
16:10-16:15 Stretch break
16:15-17:15 Session 5 – Carbapenem resistance in Enterobacterales (chair Kaisu Rantakokko-Jalava)
· NordicAST new BL/BLI document- how to use it (Arnfinn Sundsfjord)
· Background for new carbapenem breakpoints and comments (Barbara Holzknecht)
· Updated CPE screening document – experience from Karolinska University Hospital with an additional CPE-screening agar (Anna-Karin Smekal)
Wed 13 May 2026
8:30-9:15 Session 6 – Carbapenem resistance in Pseudomonas aeruginosa beyond MBL
(chair Karianne Gammelsrud)
· Resistance mechanisms other than carbapenemases, including treatment options (online: Christian Giske)
· Carbapenemases other than MBL- insights from an outbreak. Is our screening algorithm good enough? (Anna Karin Smekal)
9:15-9:20 Stretch break
9:20-10:20 Session 7 – Mini oral presentations (chair Robert Skov)
· Evaluation of meropenem and ertapenem disks from four manufacturers and broth microdilution for screening for carbapenemases in Enterobacterales (Lized Rodriguez)
· In Vitro Activity of Cefiderocol Against Carbapenemase-Producing E. coli: phenomics versus genomics for antimicrobial susceptibility prediction (Chaitanya Tellapragada)
· Vancomycin-variable enterococci (VVE) increase in Sweden 2025, VVE detected in three different clusters (Caroline Kaipe)
· One year real-life evaluation of the EUCAST RAST method (Per Rydström)
· Evaluation of Micronaut-AM for Antifungal susceptibility testing (AFST) of Candida spp. (Anna Petersson)
· Phage-Antibiotic synergy in the treatment of extensively drug-resistant Klebsiella pneumoniae chronic osteomyelitis following battlefield trauma (Dace Eglite)
10.20-10:50 Coffee
10:50-11:50 Session 8 – How to use Quality control to increase AST quality in your lab
(chair Nathalie Friberg)
· Lessons learned from Internal Quality control (Erika Matuschek, Anna Hill, Dennis Holmgaard)
· External Quality Assessment (Kaisu Rantakokko-Jalava, Dennis Holmgaard, Ingvild Haugan)
11:50-12:50 Lunch
12:50-13:35 Session 9– Keynote lecture (chair Dennis Holmgaard)
· What is going on with Haemophilus influenzae? – Update on epidemiology and AST (Dagfinn Skaare)
13:35-13:40 Stretch break
13:40-14:20 Session 10 – ESBL epidemiology (chair Anna Hill)
· ESBL - E.coli in Finland: What can we learn from the Finnish surveillance data? (Heikki Ilmavirta)
· ESBL in Stockholm: How WGS surveillance revealed a K. quasipneumoniae CTX-M outbreak (Anna-Karin Smekal)
14:20-15:00 Session 11 - Round table: Q & A from participants Moderators: Karianne Gammelsrud and Erika Matuschek
15.00-15.10 Ending of workshop, see you next year and coffee (Barbara Holzknecht)